Abstract:A strategy is presented to augment the protein degradation capability of proteolysis targeting chimeras (PROTACs) by modulating external nutrient supply and employing nanocarrier‐based targeted delivery. The results demonstrate that a reduction in nutrient supply can enhance protein metabolism and significantly improve the therapeutic efficacy of PROTACs when combined with nanocarriers. The ubiquitin‐proteasome system (UPS) is responsible for degrading over 70–80% of cellular proteins. Consequently, proteolysis‐targeting chimeras (PROTACs) are developed to induce the ubiquitination and subsequent degradation of proteins of interest (POIs) by the UPS. To amplify the therapeutic efficacy of PROTACs, energy metabolism regulation is first harnessed to boost UPS function in tumor cells. Proteomic and ubiquitinome analyzes reveal that total ubiquitinated proteins and proteasome activity are significantly increased in 143B and MDA‐MB‐231 tumor cells following fasting‐mimicking diet (FMD) treatment. As a result, the degradation efficiency of PROTACs targeting focal adhesion kinase (FAK‐P) or bromodomain‐containing protein 4 (BRD4‐P) is significantly enhanced in FMD‐treated 143B and MDA‐MB‐231 tumor cells. Then, silica‐coated iron oxide nanoparticles are developed modified with tumor cell membranes for targeted delivery of PROTACs. Magnetic resonance imaging (MRI) and fluorescence imaging confirm that nanocarriers significantly improve the delivery efficiency of PROTACs in FMD‐treated 143B or MDA‐MB‐231 tumors. In vivo studies demonstrate that the antitumor efficacy of FAK‐P and BRD4‐P is greatly augmented when combined with targeted delivery and FMD treatment. Overall, this study presents a strategy to enhance the efficacy of PROTACs in cancer therapy.

A Photoactivatable Upconverting Nanodevice Boosts the Lysosomal Escape of PROTAC Degraders for Enhanced Combination Therapy

A Photoactivatable Upconverting Nanodevice Boosts Lysosomal Escape of PROTAC Degraders for Enhanced Combination Therapy

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment

Augmenting Protein Degradation Capacity of PROTAC through Energy Metabolism Regulation and Targeted Drug Delivery

Selective Protein of Interest Degradation Through the Split-and-Mix Liposome Proteolysis Targeting Chimera Approach.

A PROTAC Augmenter for Photo‐driven Pyroptosis in Breast Cancer

Versatile Split-and-Mix Liposome PROTAC Platform for Efficient Degradation of Target Protein in Vivo

Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death

Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation

Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors

Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Precise Modulation of Protein Degradation by Smart PROTACs

Current strategies for improving limitations of proteolysis targeting chimeras

A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy

Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy

Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery